Navigation Links
bwin and Harvard Medical School Faculty Sign 5-Year Research Cooperation Agreement
Date:12/15/2008

VIENNA, Austria, December 15 /PRNewswire-FirstCall/ -- bwin, the world's leading online gaming company, and the Division on Addictions at the Cambridge Health Alliance, a Harvard Medical School Teaching Affiliate, have just signed an agreement for research collaboration for five years. The research objective is to use scientific evidence to create the safest possible online gaming environment by implementing the findings of the world's largest longitudinal study.

The Division on Addictions at the Cambridge Health Alliance, a Harvard Medical School Teaching Affiliate, has been working with bwin for the last three years setting new standards for the industry, developing and testing empirically-supported new responsible gaming initiatives, and providing customers with responsible gaming information and tools. This research has just been extended for another five years. The prime research objective is to establish a scientific evidence base that can guide the development of safe, recreational gaming environments and prevent the emergence of gaming-related problems as well as reduce any such problems that already exist.

"bwin has taken the industry's leading position for corporate social responsibility. Their commitment to the scientific process and unwillingness to take shortcuts to achieve short-term gains is noteworthy and indicative of its commitment to the health and welfare of its subscribers. Through its relationship with the Division on Addictions, bwin has supported numerous scientific inquiries, including the first ever scientific longitudinal study of actual internet gaming behavior, numerous scientific publications, and editorial position statements. bwin has integrated responsible gaming efforts into its business practices and made empirically-supported self-help resources available to its subscribers," says Dr. Howard Shaffer, Associate professor at Harvard Medical School and Director of the Division on Addictions.

The scientific studies analyzed the data of over 47,000 customers over a 36-month period, making it the largest longitudinal study of its kind worldwide. Because it relies on actual customer data and not self-reported results, the results are not influenced by customer recall or interpretation. The intention is to expand and enhance the responsible gaming activities into a systematic program of responsible gaming tools and applications.

"We need to understand what goes on in consumers' minds and be able to answer fundamental questions about online gaming based on scientific evidence - and not based on speculation. Ultimately, we are interested in creating behavioral models capable of predicting certain outcomes. Therefore, we are working towards establishing the scientific foundation that will yield algorithms capable of identifying risk patterns associated with disordered gambling so that we can prevent them," states Manfred Bodner, Co-CEO of bwin.

    For further inquiries:

    Press:

    Kevin O'Neal, Press Officer
    bwin Interactive Entertainment AG
    Borsegasse 11, 1010 Vienna, Austria
    Tel.: +43(0)50-858-24010
    E-mail: press@bwin.org

   http://www.bwin.ag

    Investors:

    Konrad Sveceny, Investor Relations
    bwin Interactive Entertainment AG
    Borsegasse 11, 1010 Vienna, Austria
    Tel.: +43(0)50-858-20017
    E-mail: investorrelations@bwin.org

   http://www.bwin.ag



'/>"/>
SOURCE bwin Interactive Entertainment AG
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Isilon CTO Addresses Life Science Data Storage Challenges at Harvard Medical Schools BioMedical HPC Leadership Summit
2. HistoRx Announces Expanded Access of AQUA(R) Technology to 900+ Researchers at Dana-Farber/Harvard Cancer Center
3. Open Biosystems Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina
4. Egenix Licenses Harvard Anti-Cancer Platform
5. Harvard University engineers demonstrate quantum cascade laser nanoantenna
6. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
7. BioMS Medical recognized at Scrip Awards 2008
8. Oridion Announces Significant Medical Research to be Presented at AARC Congress
9. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
10. Life Science Alley: R&D Makes German Medical Technologies Top in Europe
11. ATS Medical Provides Update on US Commercialization of Its ATS 3f Aortic Bioprosthesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... , ... January 11, 2017 , ... ... Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ... median 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated patients saw ...
(Date:1/11/2017)... ... January 11, 2017 , ... As ... in Peru studying the pathogens that cause malaria and tuberculosis. Seeing firsthand the ... of discovery. , Now, as an assistant professor of biology and biotechnology at ...
(Date:1/11/2017)... 2017  Brian Mehling, M.D., world-renowned stem cell researcher, ... International (BHI), will be attending the 47th Annual World ... from January 17-20, 2017. This will be Dr. Mehling,s ... theme of this year,s forum is Responsive and Responsible ... address strategies for fostering greater social inclusion and human ...
(Date:1/11/2017)... ... January 11, 2017 , ... While the most ... it is becoming increasingly clear that the evolution and transmission dynamics of resistance ... in the study of clinical resistance, has vastly underestimated these reservoirs of resistance ...
Breaking Biology Technology:
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)... VANCOUVER, Canada and BADEN-BADEN, Germany ... Solutions, a leading global financial services provider, today announced an ... in passive behavioural biometrics, to join forces. The partnership will ... fraud mitigation strategies in compliance with local data protection regulation. ... In ...
Breaking Biology News(10 mins):